Company / Cost of Revenue
ALNYLAM PHARMACEUTICALS, INC. Cost of Revenue History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$677.2M
FY2025
5-year range
$25.1M / $677.2M
FY2021-FY2025
Trend
+120.9%
vs FY2024
Sector context
#21 of 85
Health Care
What the data says
ALNYLAM PHARMACEUTICALS, INC.'s cost of revenue of $677M is higher than 75% of companies in the Health Care sector (FY2025). Cost of Revenue has increased for 6 consecutive years, from $0 in FY2019 to $677M in FY2025.
Based on SEC 10-K filings.
$677M in FY2025 with a 5-year CAGR of +227.3%. Top quartile in the Health Care sector.
Increased from $268M to $677M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +109.0%
- 5-Year CAGR
- +227.3%
- 10-Year CAGR
- -
Sector benchmark
-65.8% below sector average
Key checks
Key Insights
- ALNYLAM PHARMACEUTICALS, INC.'s cost of revenue has grown for 5 consecutive years.
- 5-year CAGR of +227.3%, indicating consistent growth.
- In FY2025, cost of revenue increased 120.9% year-over-year.
- Ranks #21 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $677.2M | +120.9% |
| FY2024 | $306.5M | +14.3% |
| FY2023 | $268.2M | +261.6% |
| FY2022 | $74.2M | +196.0% |
| FY2021 | $25.1M | +1290.8% |
| FY2020 | $1.8M | - |
| FY2019 | $0 | -100.0% |
| FY2018 | $1.8M | - |
| FY2017 | $0 | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026